Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment40
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance38
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis27
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review24
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer21
Editorial Board18
Military exposures and lung cancer in United States Veterans16
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics16
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations15
Table of Contents14
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer13
Editorial Board12
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans12
Role of neoadjuvant pembrolizumab in advanced melanoma12
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis11
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review11
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response11
Editorial Board11
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer10
Masthead10
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.9
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment9
Masthead9
Acute liver failure secondary to malignant infiltration: A single center experience9
Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran8
Editorial Board8
Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use8
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)8
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review7
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward7
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t7
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer7
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population6
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors6
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities6
Barriers and facilitators to lung cancer screening and follow-up6
Masthead6
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care6
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects6
Current and prospective antibody-based therapies in multiple myeloma5
Editorial Board5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty5
A narrative review of the principal glucocorticoids employed in cancer5
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy5
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment5
outside front cover5
Radiation recall dermatitis: A review of the literature5
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Daratumumab: A review of current indications and future directions4
Masthead4
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety4
Masthead4
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data4
Table of Contents4
Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia4
Are we there yet? Gut microbiota for cancer diagnosis, prognosis and treatment4
0.041805028915405